Cynvenio Biosystems ClearID HER2 Expression Test
Aug 24, 2017
Cynvenio Biosystems launched its ClearID HER2 Expression Test. The liquid biopsy test allows doctors to perform real-time monitoring and analysis of HER2 levels in patients with a normal blood draw. It leverages Cynvenio's liquid biopsy technology and uses antibodies against EpCAM, TROP2, HER2, and EGFR. The test has a turnaround time of three to seven days and is processed by Cynvenio's CLIA/CAP laboratory in California.